These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

244 related articles for article (PubMed ID: 26232269)

  • 1. Clinical usefulness of the ablative margin assessed by magnetic resonance imaging with Gd-EOB-DTPA for radiofrequency ablation of hepatocellular carcinoma.
    Koda M; Tokunaga S; Okamoto T; Hodozuka M; Miyoshi K; Kishina M; Fujise Y; Kato J; Matono T; Sugihara T; Oyama K; Hosho K; Okano J; Murawaki Y; Kakite S; Yamashita E
    J Hepatol; 2015 Dec; 63(6):1360-7. PubMed ID: 26232269
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Ablative margin states by magnetic resonance imaging with ferucarbotran in radiofrequency ablation for hepatocellular carcinoma can predict local tumor progression.
    Koda M; Tokunaga S; Miyoshi K; Kishina M; Fujise Y; Kato J; Matono T; Murawaki Y; Kakite S; Yamashita E
    J Gastroenterol; 2013 Nov; 48(11):1283-92. PubMed ID: 23338488
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Comparative evaluation of three-dimensional Gd-EOB-DTPA-enhanced MR fusion imaging with CT fusion imaging in the assessment of treatment effect of radiofrequency ablation of hepatocellular carcinoma.
    Makino Y; Imai Y; Igura T; Hori M; Fukuda K; Sawai Y; Kogita S; Fujita N; Takehara T; Murakami T
    Abdom Imaging; 2015 Jan; 40(1):102-11. PubMed ID: 25052767
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Assessment of ablative margin by unenhanced magnetic resonance imaging after radiofrequency ablation for hepatocellular carcinoma.
    Koda M; Tokunaga S; Miyoshi K; Kishina M; Fujise Y; Kato J; Matono T; Okamoto K; Murawaki Y; Kakite S
    Eur J Radiol; 2012 Oct; 81(10):2730-6. PubMed ID: 22137612
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Imaging evaluation of ablative margin and index tumor immediately after radiofrequency ablation for hepatocellular carcinoma: comparison between multidetector-row CT and MR imaging.
    Kim SM; Shin SS; Lee BC; Kim JW; Heo SH; Lim HS; Jeong YY
    Abdom Radiol (NY); 2017 Oct; 42(10):2527-2537. PubMed ID: 28409202
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Assessment of ablative margin after radiofrequency ablation for hepatocellular carcinoma; comparison between magnetic resonance imaging with ferucarbotran and enhanced CT with iodized oil deposition.
    Koda M; Tokunaga S; Fujise Y; Kato J; Matono T; Sugihara T; Nagahara T; Ueki M; Murawaki Y; Kakite S; Yamashita E
    Eur J Radiol; 2012 Jul; 81(7):1400-4. PubMed ID: 21440397
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Non-Hypervascular Hypointense Hepatic Nodules during the Hepatobiliary Phase of Gadolinium-Ethoxybenzyl-Diethylenetriamine Pentaacetic Acid-Enhanced MRI as a Risk Factor of Intrahepatic Distant Recurrence after Radiofrequency Ablation of Hepatocellular Carcinoma.
    Iwamoto T; Imai Y; Igura T; Kogita S; Sawai Y; Fukuda K; Yamaguchi Y; Matsumoto Y; Nakahara M; Morimoto O; Ohashi H; Fujita N; Kudo M; Takehara T
    Dig Dis; 2017; 35(6):574-582. PubMed ID: 29040990
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Assessment of ablative margin by MRI with ferucarbotran in radiofrequency ablation for liver cancer: comparison with enhanced CT.
    Tokunaga S; Koda M; Matono T; Sugihara T; Nagahara T; Ueki M; Murawaki Y; Kakite S; Yamashita E
    Br J Radiol; 2012 Jun; 85(1014):745-52. PubMed ID: 21385915
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Presence of non-hypervascular hypointense nodules on Gadolinium-ethoxybenzyl-diethylenetriamine pentaacetic acid-enhanced magnetic resonance imaging in patients with hepatocellular carcinoma.
    Inoue M; Ogasawara S; Chiba T; Ooka Y; Wakamatsu T; Kobayashi K; Suzuki E; Tawada A; Yokosuka O
    J Gastroenterol Hepatol; 2017 Apr; 32(4):908-915. PubMed ID: 27787908
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Non-hypervascular hypointense nodules on Gd-EOB-DTPA-enhanced MRI as a predictor of outcomes for early-stage HCC.
    Toyoda H; Kumada T; Tada T; Sone Y; Maeda A; Kaneoka Y
    Hepatol Int; 2015 Jan; 9(1):84-92. PubMed ID: 25788383
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Non-hypervascular hepatobiliary phase hypointense nodules on gadoxetic acid-enhanced MRI: risk of HCC recurrence after radiofrequency ablation.
    Lee DH; Lee JM; Lee JY; Kim SH; Kim JH; Yoon JH; Kim YJ; Lee JH; Yu SJ; Han JK; Choi BI
    J Hepatol; 2015 May; 62(5):1122-30. PubMed ID: 25529623
    [TBL] [Abstract][Full Text] [Related]  

  • 12. The minimal ablative margin of radiofrequency ablation of hepatocellular carcinoma (> 2 and < 5 cm) needed to prevent local tumor progression: 3D quantitative assessment using CT image fusion.
    Kim YS; Lee WJ; Rhim H; Lim HK; Choi D; Lee JY
    AJR Am J Roentgenol; 2010 Sep; 195(3):758-65. PubMed ID: 20729457
    [TBL] [Abstract][Full Text] [Related]  

  • 13. A non-smooth tumor margin in the hepatobiliary phase of gadoxetic acid disodium (Gd-EOB-DTPA)-enhanced magnetic resonance imaging predicts microscopic portal vein invasion, intrahepatic metastasis, and early recurrence after hepatectomy in patients with hepatocellular carcinoma.
    Ariizumi S; Kitagawa K; Kotera Y; Takahashi Y; Katagiri S; Kuwatsuru R; Yamamoto M
    J Hepatobiliary Pancreat Sci; 2011 Jul; 18(4):575-85. PubMed ID: 21360083
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Therapy response assessment after radioembolization of patients with hepatocellular carcinoma--comparison of MR imaging with gadolinium ethoxybenzyl diethylenetriamine penta-acetic acid and gadobutrol.
    Schelhorn J; Best J; Reinboldt MP; Gerken G; Ruhlmann M; Lauenstein TC; Antoch G; Kinner S
    J Vasc Interv Radiol; 2015 Jul; 26(7):972-9. PubMed ID: 25937296
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Rate of local tumor progression following radiofrequency ablation of pathologically early hepatocellular carcinoma.
    Hao Y; Numata K; Ishii T; Fukuda H; Maeda S; Nakano M; Tanaka K
    World J Gastroenterol; 2017 May; 23(17):3111-3121. PubMed ID: 28533668
    [TBL] [Abstract][Full Text] [Related]  

  • 16. T1 mapping combined with Gd-EOB-DTPA-enhanced magnetic resonance imaging in predicting the pathologic grading of hepatocellular carcinoma.
    Chen CY; Chen J; Xia CC; Huang ZX; Song B
    J Biol Regul Homeost Agents; 2017; 31(4):1029-1036. PubMed ID: 29254310
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Fusion imaging with contrast-enhanced ultrasonography for evaluating the early therapeutic efficacy of radiofrequency ablation for small hypervascular hepatocellular carcinomas with iso-echoic or unclear margins on conventional ultrasonography.
    Nishigori S; Numata K; Irie K; Fukuda H; Chuma M; Maeda S
    J Med Ultrason (2001); 2018 Jul; 45(3):405-415. PubMed ID: 29362966
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Intra-individual comparison of hepatocellular carcinoma imaging features on contrast-enhanced computed tomography, gadopentetate dimeglumine-enhanced MRI, and gadoxetic acid-enhanced MRI.
    Kim YN; Song JS; Moon WS; Hwang HP; Kim YK
    Acta Radiol; 2018 Jun; 59(6):639-648. PubMed ID: 28825310
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Prediction of Local Tumor Progression after Radiofrequency Ablation (RFA) of Hepatocellular Carcinoma by Assessment of Ablative Margin Using Pre-RFA MRI and Post-RFA CT Registration.
    Yoon JH; Lee JM; Klotz E; Woo H; Yu MH; Joo I; Lee ES; Han JK
    Korean J Radiol; 2018; 19(6):1053-1065. PubMed ID: 30386137
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Does diffusion-weighted imaging improve therapy response evaluation in patients with hepatocellular carcinoma after radioembolization? comparison of MRI using Gd-EOB-DTPA with and without DWI.
    Schelhorn J; Best J; Reinboldt MP; Dechêne A; Gerken G; Ruhlmann M; Lauenstein TC; Antoch G; Kinner S
    J Magn Reson Imaging; 2015 Sep; 42(3):818-27. PubMed ID: 25515676
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 13.